Summit continues to make strong progress with its lead programmes, SMT C1100 for Duchenne Muscular Dystrophy (DMD) and SMT 19969 for C. difficile infection, both of which are on track to deliver data in H2 2015. The main highlights during Q1 2016 were the dosing of the first patients in a Phase Ib modified diet clinical trial of SMT C1100 and the successful $39.3m ADS offering and NASDAQ listing. The offering enables the group to progress its development programmes. There is currently no cure fo ....
